February is Heart Month, a time to focus on the health and well-being of Ontarians. In recognition of this, and in advance of the upcoming provincial election, we are calling on all political parties ...

Scholar Rock (NASDAQ: SRRK ... the Compensation Committee of Savara's Board of Directors... Acadia Pharmaceuticals Inc. today announced that on February 6, 2025, the Compensation Committee ...

Our top contributor for the quarter was biotech company Scholar Rock (SRRK), which rallied over 300% in the days following the news that its candidate for spinal muscular atrophy, apitegromab ...

sending the shares of rival Scholar Rock, which is developing a similar drug, up 31%. Sage Therapeutics said on Wednesday it would stop the development of its experimental drug following the ...

CAMBRIDGE, Mass., February 14, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders ...

KBC Group NV purchased a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 3,020 shares of the company’s ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

CAMBRIDGE, Mass., February 14, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular ...